Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients
with advanced gastric or gastroesophageal junction cancer. Akt inhibitor MK2206 may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.